2222115-55-9

Basic information

• Product Name: methyl 4-((tert-butyldimethylsilyl)oxy)-2-methylbenzoate
• CAS NO: 2222115-55-9
• Molecular Weight: 280.439
• Mol File: 2222115-55-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: methyl 4-((tert-butyldimethylsilyl)oxy)-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-((tert-butyldimethylsilyl)oxy)-2-methylbenzoate(2222115-55-9)
• EPA Substance Registry System: methyl 4-((tert-butyldimethylsilyl)oxy)-2-methylbenzoate(2222115-55-9)

Safety Data

• Hazardous Substances Data: 2222115-55-9(Hazardous Substances Data)

Upstream product

• 578-39-2 4-hydroxy-2-methylbenzoic acid 
• 57556-31-7 4-hydroxy-2-methylbenzoic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 2375482-51-0 (S)-5-hydroxy-3-[2-({[1-(1-methyl-1H-imidazol-4-ylmethyl)-1H-indol-6-ylmethyl]amino}methyl)-1H-indol-3-yl]-2,3-dihydroisoindol-1-one 
• 2375482-51-0 (R)-5-hydroxy-3-[2-({[1-(1-methyl-1H-imidazol-4-ylmethyl)-1H-indol-6-ylmethyl]amino}methyl)-1H-indol-3-yl]-2,3-dihydroisoindol-1-one 
• 2375482-51-0 5-hydroxy-3-[2-({[1-(1-methyl-1H-imidazol-4-ylmethyl)-1H-indol-6-ylmethyl]amino}methyl)-1H-indol-3-yl]-2,3-dihydroisoindol-1-one 

Relevant articles and documents

Development of Photolenalidomide for Cellular Target Identification

The thalidomide analogue lenalidomide (Len) is a clinical therapeutic that alters the substrate engagement of cereblon (CRBN), a substrate receptor for the CRL4 E3 ubiquitin ligase. Here, we report the development of photolenalidomide (pLen), a Len probe with a photoaffinity label and enrichment handle, designed for target identification by chemical proteomics. pLen preserves the substrate degradation profile, phenotypic antiproliferative and immunomodulatory properties of Len, and enhances interactions with the thalidomide-binding domain of CRBN, as revealed by binding site mapping and molecular modeling. Using pLen, we captured the known targets IKZF1 and CRBN from multiple myeloma MM.1S cells and further identified a new target, eukaryotic translation initiation factor 3 subunit i (eIF3i), from HEK293T cells. eIF3i is directly labeled by pLen and forms a ternary complex with CRBN in the presence of Len across several epithelial cell lines but is itself not ubiquitylated or degraded. These data point to the existence of a broader array of targets induced by ligands to CRBN that may or may not be degraded, which can be identified by the highly translatable application of pLen to additional biological systems.

NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS

-The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.